arrow
L

Laura Stanbery

gradalis inc
H指数:20
被引数:1,711

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Exome sequencing shows same pattern of clonal tumor mutational burden, intratumor heterogenicity and clonal neoantigen between autologous tumor and Vigil product

外显子组测序显示自体肿瘤和Vigil产物之间的克隆肿瘤突变负荷,肿瘤内异质性和克隆新抗原的相同模式

2025-03-131
OAAI
ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer

ENTPD1/CD39作为新诊断卵巢癌维持治疗对吉非替尼治疗反应的预测指标

2022-08-2911
OA
Proof of principle study of sequential combination atezolizumab and Vigil in relapsed ovarian cancer
2021-03-2217
OAAI